These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28296398)

  • 1. Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
    Burks HE; Abrams T; Kirby CA; Baird J; Fekete A; Hamann LG; Kim S; Lombardo F; Loo A; Lubicka D; Macchi K; McDonnell DP; Mishina Y; Norris JD; Nunez J; Saran C; Sun Y; Thomsen NM; Wang C; Wang J; Peukert S
    J Med Chem; 2017 Apr; 60(7):2790-2818. PubMed ID: 28296398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
    Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
    J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
    Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
    J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
    Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
    Liang J; Zbieg JR; Blake RA; Chang JH; Daly S; DiPasquale AG; Friedman LS; Gelzleichter T; Gill M; Giltnane JM; Goodacre S; Guan J; Hartman SJ; Ingalla ER; Kategaya L; Kiefer JR; Kleinheinz T; Labadie SS; Lai T; Li J; Liao J; Liu Z; Mody V; McLean N; Metcalfe C; Nannini MA; Oeh J; O'Rourke MG; Ortwine DF; Ran Y; Ray NC; Roussel F; Sambrone A; Sampath D; Schutt LK; Vinogradova M; Wai J; Wang T; Wertz IE; White JR; Yeap SK; Young A; Zhang B; Zheng X; Zhou W; Zhong Y; Wang X
    J Med Chem; 2021 Aug; 64(16):11841-11856. PubMed ID: 34251202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
    Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
    Garner F; Shomali M; Paquin D; Lyttle CR; Hattersley G
    Anticancer Drugs; 2015 Oct; 26(9):948-56. PubMed ID: 26164151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
    Scott JS; Moss TA; Balazs A; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Davey PRJ; Delpuech O; Fawell S; Fisher DI; Gagrica S; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Herlihy K; Hughes S; Hunt TA; Huynh H; Janbon SLM; Johnson T; Kavanagh S; Klinowska T; Lawson M; Lister AS; Marden S; McGinnity DF; Morrow CJ; Nissink JWM; O'Donovan DH; Peng B; Polanski R; Stead DS; Stokes S; Thakur K; Throner SR; Tucker MJ; Varnes J; Wang H; Wilson DM; Wu D; Wu Y; Yang B; Yang W
    J Med Chem; 2020 Dec; 63(23):14530-14559. PubMed ID: 32910656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
    Yu W; Li C; Zhang W; Xia Y; Li S; Lin JY; Yu K; Liu M; Yang L; Luo J; Chen Y; Sun H; Kong L
    J Med Chem; 2017 Apr; 60(7):2718-2731. PubMed ID: 28245116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
    Scott JS; Stead D; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Cureton N; Davey PRJ; Fisher DI; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Hughes SJ; Hunt TA; Johnson T; Kavanagh SL; Klinowska TCM; Larner CJB; Lawson M; Lister AS; Longmire D; Marden S; McGuire TM; McMillan C; McMurray L; Morrow CJ; Nissink JWM; Moss TA; O'Donovan DH; Polanski R; Stokes S; Thakur K; Trueman D; Truman C; Tucker MJ; Wang H; Whalley N; Wu D; Wu Y; Yang B; Yang W
    J Med Chem; 2023 Feb; 66(4):2918-2945. PubMed ID: 36727211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
    Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
    J Med Chem; 2024 Jun; 67(11):8913-8931. PubMed ID: 38809993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
    Tang Z; Niu S; Liu F; Lao K; Miao J; Ji J; Wang X; Yan M; Zhang L; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2014 May; 24(9):2129-33. PubMed ID: 24721727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
    El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
    J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
    Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
    J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
    Scott JS; Bailey A; Buttar D; Carbajo RJ; Curwen J; Davey PRJ; Davies RDM; Degorce SL; Donald C; Gangl E; Greenwood R; Groombridge SD; Johnson T; Lamont S; Lawson M; Lister A; Morrow CJ; Moss TA; Pink JH; Polanski R
    J Med Chem; 2019 Feb; 62(3):1593-1608. PubMed ID: 30640465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.